000110740 001__ 110740
000110740 005__ 20230519145623.0
000110740 0247_ $$2doi$$a10.3390/jcm10225446
000110740 0248_ $$2sideral$$a127213
000110740 037__ $$aART-2021-127213
000110740 041__ $$aeng
000110740 100__ $$aKrajewski, P.K.
000110740 245__ $$aThe use of HSQoL-24 in an assessment of quality-of-life impairment among hidradenitis suppurativa patients: First look at real-life data
000110740 260__ $$c2021
000110740 5060_ $$aAccess copy available to the general public$$fUnrestricted
000110740 5203_ $$aHidradenitis suppurativa (HS) is a chronic inflammatory skin disorder with well-documented effects on patients’ quality of life (QoL). The aim of this study was to evaluate the QoL of patients with HS via the use of a newly developed questionnaire: Hidradenitis Suppurativa Quality of Life-24 (HSQoL-24). This study was performed on a population of 342 HS patients. Their QoL was assessed via the HSQoL-24 questionnaire. The perceived impairment of QoL due to HS in the studied group was considered to be serious (mean HSQoL-24 score: 58.3 ± 21.0 points). Women tended to experience a significantly higher impact from the disease than men (61.6 ± 19.2 points vs. 51.1 ± 23.1 points, p < 0.001). The HS severity had an effect on the perceived QoL, with statistically significant differences being evident between the self-assessed HS severity groups. The level of QoL impairment correlated positively with the number of affected body areas (r = 0.285, p < 0.001) and the duration of the disease (r = 0.173, p = 0.001), while the patients’ age at disease onset correlated negatively with the HSQoL-24 global score (r = -0.182, p = 0.001). Patients living in their family house scored higher than other groups. The least affected were patients who lived alone. The study shows that the HSQoL-24 questionnaire is a reliable, HS-specific tool for measuring the QoL among patients with HS in real-life clinical settings. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
000110740 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000110740 590__ $$a4.964$$b2021
000110740 592__ $$a1.04$$b2021
000110740 594__ $$a4.4$$b2021
000110740 591__ $$aMEDICINE, GENERAL & INTERNAL$$b55 / 172 = 0.32$$c2021$$dQ2$$eT1
000110740 593__ $$aMedicine (miscellaneous)$$c2021$$dQ1
000110740 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000110740 700__ $$0(orcid)0000-0001-5632-0351$$aMarrón, S.E.$$uUniversidad de Zaragoza
000110740 700__ $$aGomez-Barrera, M.
000110740 700__ $$0(orcid)0000-0003-1917-6906$$aTomas-Aragones, L.$$uUniversidad de Zaragoza
000110740 700__ $$0(orcid)0000-0001-8034-3617$$aGilaberte-Calzada, Y.$$uUniversidad de Zaragoza
000110740 700__ $$aSzepietowski, J.C.
000110740 7102_ $$14009$$2735$$aUniversidad de Zaragoza$$bDpto. Psicología y Sociología$$cÁrea Psicolog.Evolut.Educac
000110740 7102_ $$11007$$2183$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cÁrea Dermatología
000110740 773__ $$g10, 22 (2021), 5446 [9 pp]$$pJ. clin.med.$$tJournal of Clinical Medicine$$x2077-0383
000110740 8564_ $$s266799$$uhttps://zaguan.unizar.es/record/110740/files/texto_completo.pdf$$yVersión publicada
000110740 8564_ $$s2743337$$uhttps://zaguan.unizar.es/record/110740/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000110740 909CO $$ooai:zaguan.unizar.es:110740$$particulos$$pdriver
000110740 951__ $$a2023-05-18-16:17:49
000110740 980__ $$aARTICLE